Multiple Myeloma
Conditions
Keywords
multiple myeloma, peripheral neuropathy, prophylaxis
Brief summary
Bortezomib was an important drug in the treatment of multiple myeloma (MM),and peripheral neuropathy (PN) is a significant dose-limiting toxicity of bortezomib that typically occurs within the first courses of bortezomib, reaches a plateau at cycle 5. Up to now, no effective prophylaxis have been developed for PN. Monosialotetrahexosylganglioside, a nerve-protecting drug,was often used to promote growth of nerve, and function restoration of damaged nerve.Thus,the investigators hypothesized that combination of Monosialotetrahexosylganglioside and bortezomib can reduce the incidence rate of peripheral neuropathy (PN) and promote the relief of peripheral neuropathy (PN) in multiple myeloma (MM) patients.
Interventions
Sponsors
Sun Yat-sen University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Histologic diagnosis of multiple myeloma; * Age:18-80 years; * Eastern Cooperative Oncology Group (ECOG) status 0-3, * Estimated survival time \> 3 months; * Acceptable liver function (bilirubin\<2.5×ULN, Alanine transaminase (ALT) or Aspartate Aminotransferase (AST)\<2.5×ULN), * No history of other malignancies; * No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation; * No other serious diseases which conflict with the treatment in the present trial; * No concurrent treatments that conflict with the treatments in the present trial; * Voluntary participation and signed the informed consent.
Exclusion criteria
* The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication; * The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies; * The patients with neuropathy; * The patients with mentally ill / unable to obtain informed consent; * The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results; * The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects; * The patients with a history of allergy to test drug; * The patients not suitable to participate in the investigator judged by researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall incidence rate of peripheral neuropathy (PN) | up to 6 months | the grade of peripheral neuropathy (PN) was recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of peripheral neuropathy (PN) | up to 1 year (about 6 months after the completion of treatment) | the duration of peripheral neuropathy means the time from the onset time of peripheral neuropathy (PN) to the relief time of PN |
| complete rate (CR) rate | up to 6 months | The criteria for CR was according to International Myeloma Working Group Uniform Response Criteria |
Countries
China
Contacts
Primary ContactZhong-jun Xia, M.D.
Backup ContactLiang Wang, M.D.
Outcome results
None listed